Treatment of Squamous Cell Esophageal Cancer With Topotecan
- 1 February 2000
- journal article
- clinical trial
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 23 (1) , 45-46
- https://doi.org/10.1097/00000421-200002000-00013
Abstract
Seventeen patients with enhanced measurable squamous cell carcinoma of the esophagus were treated with topotecan 1.5 mg/m2 daily for 5 days repeated every 21 days. Toxicity was severe, with 1 death from myelotoxicity and 10 patients with life-threatening myelotoxicity. Severe gastrointestinal toxicity consisting of vomiting was also seen in three patients. No response was seen in any of the patients in the study. Topotecan given in this manner has no activity in squamous cell carcinoma of the esophagus.Keywords
This publication has 7 references indexed in Scilit:
- Cancer statistics, 1998CA: A Cancer Journal for Clinicians, 1998
- DNA Topoisomerases: Essential Enzymes and Lethal TargetsAnnual Review of Pharmacology and Toxicology, 1994
- Camptothecin analogues: studies from The Johns Hopkins Oncology CenterCancer Chemotherapy and Pharmacology, 1994
- Cellular Determinants of Sensitivity and Resistance to DNA Topoisomerase InhibitorsCancer Investigation, 1994
- The Current Status of Camptothecin Analogues as Antitumor AgentsJNCI Journal of the National Cancer Institute, 1993
- Activity of Topotecan, a New Topoisomerase I Inhibitor, Against Human Tumor Colony-Forming Units In VitroJNCI Journal of the National Cancer Institute, 1992
- Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNANucleic Acids Research, 1991